- Home
- PMVP vs TLSA Comparison
PMVP vs TLSA Comparison
Compare PMVP & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PMVP | TLSA |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.0M | 182.7M |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | PMVP | TLSA |
|---|---|---|
| Price | $1.25 | $1.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 291.0K | ★ 456.5K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $0.63 |
| 52 Week High | $1.84 | $2.60 |
Technical Indicators
Market Signals| Indicator | PMVP | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 47.29 | 41.48 |
| Support Level | $1.11 | $1.39 |
| Resistance Level | $1.30 | $1.60 |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 67.50 | 41.67 |
Price Performance
Historical ComparisonAbout PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.